| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm |
| Cash burn (monthly) | 1.50 mm | 4.52 mm | 9.90 mm | 7.37 mm | 5.82 mm | 4.64 mm |
| Cash used (since last report) | 34.56 mm | 104.42 mm | 228.52 mm | 170.06 mm | 134.22 mm | 107.12 mm |
| Cash remaining | -9.90 mm | -79.77 mm | -203.86 mm | -145.41 mm | -109.57 mm | -82.47 mm |
| Runway (months of cash) | -6.6 | -17.6 | -20.6 | -19.7 | -18.8 | -17.8 |
| 13F holders | Current |
|---|---|
| Total holders | 8 |
| Opened positions | 0 |
| Closed positions | 27 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 253.96 mm |
| Total shares | 12.32 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| MPM Asset Management | 2.85 mm | $115.40 mm |
| K2 HealthVentures Equity Trust | 2.59 mm | $4.54 mm |
| MPM BioVentures 2014 | 2.40 mm | $37.31 mm |
| MPM Oncology Impact Management | 2.38 mm | $96.27 mm |
| Arkin Moshe | 1.07 mm | $0.00 |
| Flynn James E | 1.02 mm | $426.00 k |
| BCS Barclays | 9.49 k | $0.00 |
| Your Advocates | 100.00 | $4.00 k |
